Metrovacesa Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Metrovacesa wird ein jährliches Gewinn- und Umsatzwachstum von 51.4% bzw. 9.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 51.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 3.1% betragen.

Wichtige Informationen

22.3%

Wachstumsrate der Gewinne

21.8%

EPS-Wachstumsrate

Real Estate Gewinnwachstum9.2%
Wachstumsrate der Einnahmen3.1%
Zukünftige Eigenkapitalrendite2.4%
Analystenabdeckung

Low

Zuletzt aktualisiert25 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven

Feb 16
Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven

Recent updates

Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)

Sep 12
Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)

We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve

Aug 01
We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

Jul 17
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

May 28
A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt

May 01
We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

Mar 27
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

Feb 12
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Nov 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively

Jul 05
These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

May 21
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Apr 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Dec 02
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?

Sep 23
Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?

Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

May 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality

Mar 05
Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality

Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?

Feb 16
Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Oct 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?

Jul 02
Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?

Is Metrovacesa (BME:MVC) Using Too Much Debt?

May 06
Is Metrovacesa (BME:MVC) Using Too Much Debt?

Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?

Apr 06
Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?

Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years

Mar 15
Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years

Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven

Feb 16
Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven

When Should You Buy Metrovacesa S.A. (BME:MVC)?

Jan 26
When Should You Buy Metrovacesa S.A. (BME:MVC)?

A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

Jan 05
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%

Dec 14
If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%

Gewinn- und Umsatzwachstumsprognosen

BME:MVC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202667931132873
12/31/2025734411352115
12/31/2024650221201083
6/30/2024649185555N/A
3/31/2024616-15N/AN/AN/A
12/31/2023581-213232N/A
9/30/2023535-68N/AN/AN/A
6/30/2023430-719292N/A
3/31/2023454-38N/AN/AN/A
12/31/2022516-23211211N/A
9/30/202252925N/AN/AN/A
6/30/202257233227227N/A
3/31/202257531N/AN/AN/A
12/31/202151218139139N/A
9/30/2021413-71N/AN/AN/A
6/30/2021231-90-24-24N/A
3/31/2021138-160N/AN/AN/A
12/31/2020140-164-78-78N/A
9/30/2020164-87N/AN/AN/A
6/30/2020180-87-46-45N/A
3/31/2020214-6N/AN/AN/A
12/31/2019161-4-29-28N/A
9/30/20192060-15-15N/A
6/30/201922051718N/A
3/31/2019211-112021N/A
12/31/2018190-93435N/A
9/30/2018103-14147147N/A
6/30/201870-31-20-19N/A
3/31/201834-34N/A-38N/A
12/31/201728-39N/A-27N/A
9/30/201729-55N/A-172N/A
12/31/201621-21N/A21N/A
12/31/20153664N/A-62N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MVCDas prognostizierte Gewinnwachstum (20.8% pro Jahr) liegt über der Sparquote (1.5%).

Ertrag vs. Markt: MVCDie Erträge des Unternehmens (20.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Spanish (9.6% pro Jahr).

Hohe Wachstumserträge: MVCEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: MVCDie Einnahmen des Unternehmens (3.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Spanish (4.7% pro Jahr).

Hohe Wachstumseinnahmen: MVCDie Einnahmen des Unternehmens (9.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MVCDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (3.1%).


Wachstumsunternehmen entdecken